Literature DB >> 26524606

Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2.

Andrew S Felts1, Alice L Rodriguez1, Katrina A Smith1, Julie L Engers1, Ryan D Morrison1, Frank W Byers1, Anna L Blobaum1, Charles W Locuson1, Sichen Chang1, Daryl F Venable1, Colleen M Niswender1, J Scott Daniels1, P Jeffrey Conn1, Craig W Lindsley1,2, Kyle A Emmitte1,2.   

Abstract

Both orthosteric and allosteric antagonists of the group II metabotropic glutamate receptors (mGlus) have been used to establish a link between mGlu2/3 inhibition and a variety of CNS diseases and disorders. Though these tools typically have good selectivity for mGlu2/3 versus the remaining six members of the mGlu family, compounds that are selective for only one of the individual group II mGlus have proved elusive. Herein we report on the discovery of a potent and highly selective mGlu2 negative allosteric modulator 58 (VU6001192) from a series of 4-oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides. The concept for the design of this series centered on morphing a quinoline series recently disclosed in the patent literature into a chemotype previously used for the preparation of muscarinic acetylcholine receptor subtype 1 positive allosteric modulators. Compound 58 exhibits a favorable profile and will be a useful tool for understanding the biological implications of selective inhibition of mGlu2 in the CNS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26524606      PMCID: PMC4817271          DOI: 10.1021/acs.jmedchem.5b01371

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  56 in total

1.  MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

Authors:  Shigeyuki Chaki; Ryoko Yoshikawa; Shiho Hirota; Toshiharu Shimazaki; Maoko Maeda; Naoya Kawashima; Takao Yoshimizu; Akito Yasuhara; Kazunari Sakagami; Shigeru Okuyama; Shigetada Nakanishi; Atsuro Nakazato
Journal:  Neuropharmacology       Date:  2004-03       Impact factor: 5.250

Review 2.  Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.

Authors:  Albert J Robichaud; Darren W Engers; Craig W Lindsley; Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2011-06-14       Impact factor: 4.418

3.  Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice.

Authors:  Yukio Ago; Koji Yano; Ryota Araki; Naoki Hiramatsu; Yuki Kita; Toshiyuki Kawasaki; Hirotaka Onoe; Shigeyuki Chaki; Atsuro Nakazato; Hitoshi Hashimoto; Akemichi Baba; Kazuhiro Takuma; Toshio Matsuda
Journal:  Neuropharmacology       Date:  2012-09-25       Impact factor: 5.250

4.  The selective reaction of aryl halides with KOH: synthesis of phenols, aromatic ethers, and benzofurans.

Authors:  Kevin W Anderson; Takashi Ikawa; Rachel E Tundel; Stephen L Buchwald
Journal:  J Am Chem Soc       Date:  2006-08-23       Impact factor: 15.419

5.  Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM.

Authors:  Douglas J Sheffler; Cody J Wenthur; Joshua A Bruner; Sheridan J S Carrington; Paige N Vinson; Kiran K Gogi; Anna L Blobaum; Ryan D Morrison; Mitchell Vamos; Nicholas D P Cosford; Shaun R Stauffer; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2012-04-30       Impact factor: 2.823

6.  Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism.

Authors:  Thomas M Bridges; Jerri M Rook; Meredith J Noetzel; Ryan D Morrison; Ya Zhou; Rocco D Gogliotti; Paige N Vinson; Zixiu Xiang; Carrie K Jones; Colleen M Niswender; Craig W Lindsley; Shaun R Stauffer; P Jeffrey Conn; J Scott Daniels
Journal:  Drug Metab Dispos       Date:  2013-07-02       Impact factor: 3.922

7.  Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression.

Authors:  Hiroyuki Koike; Kenichi Fukumoto; Michihiko Iijima; Shigeyuki Chaki
Journal:  Behav Brain Res       Date:  2012-10-23       Impact factor: 3.332

Review 8.  Metabotropic glutamate receptors: physiology, pharmacology, and disease.

Authors:  Colleen M Niswender; P Jeffrey Conn
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

9.  Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM).

Authors:  Cody J Wenthur; Ryan Morrison; Andrew S Felts; Katrina A Smith; Julie L Engers; Frank W Byers; J Scott Daniels; Kyle A Emmitte; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2013-06-13       Impact factor: 7.446

10.  Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.

Authors:  James C Tarr; Mark L Turlington; Paul R Reid; Thomas J Utley; Douglas J Sheffler; Hyekyung P Cho; Rebecca Klar; Tristano Pancani; Michael T Klein; Thomas M Bridges; Ryan D Morrison; Anna L Blobaum; Zixui Xiang; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Michael R Wood; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2012-07-18       Impact factor: 4.418

View more
  10 in total

Review 1.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

2.  Metabotropic glutamate receptor 2 inhibits thalamically-driven glutamate and dopamine release in the dorsal striatum.

Authors:  Kari A Johnson; Yolanda Mateo; David M Lovinger
Journal:  Neuropharmacology       Date:  2017-01-31       Impact factor: 5.250

3.  Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu3 NAMs.

Authors:  Julie L Engers; Katrina A Bollinger; Rebecca L Weiner; Alice L Rodriguez; Madeline F Long; Megan M Breiner; Sichen Chang; Sean R Bollinger; Michael Bubser; Carrie K Jones; Ryan D Morrison; Thomas M Bridges; Anna L Blobaum; Colleen M Niswender; P Jeffrey Conn; Kyle A Emmitte; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2017-08-15       Impact factor: 4.345

4.  Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core.

Authors:  Katrina A Bollinger; Andrew S Felts; Christopher J Brassard; Julie L Engers; Alice L Rodriguez; Rebecca L Weiner; Hyekyung P Cho; Sichen Chang; Michael Bubser; Carrie K Jones; Anna L Blobaum; Colleen M Niswender; P Jeffrey Conn; Kyle A Emmitte; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2017-08-03       Impact factor: 4.345

5.  Differential Pharmacology and Binding of mGlu2 Receptor Allosteric Modulators.

Authors:  Daniel E O'Brien; Douglas M Shaw; Hyekyung P Cho; Alan J Cross; Steven S Wesolowski; Andrew S Felts; Jonas Bergare; Charles S Elmore; Craig W Lindsley; Colleen M Niswender; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2018-03-15       Impact factor: 4.436

6.  Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a logD Lowering Twist.

Authors:  Sébastien L Degorce; Michael S Bodnarchuk; James S Scott
Journal:  ACS Med Chem Lett       Date:  2019-07-18       Impact factor: 4.345

7.  Synthesis and Characterization of 5-(2-Fluoro-4-[11C]methoxyphenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-7-carboxamide as a PET Imaging Ligand for Metabotropic Glutamate Receptor 2.

Authors:  Gengyang Yuan; Maeva Dhaynaut; Yu Lan; Nicolas J Guehl; Dalena Huynh; Suhasini M Iyengar; Sepideh Afshar; Manish Kumar Jain; Julie E Pickett; Hye Jin Kang; Hao Wang; Sung-Hyun Moon; Mary Jo Ondrechen; Changning Wang; Timothy M Shoup; Georges El Fakhri; Marc D Normandin; Anna-Liisa Brownell
Journal:  J Med Chem       Date:  2022-01-28       Impact factor: 8.039

8.  Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for Imaging of Metabotropic Glutamate Receptor 2.

Authors:  Xiaofei Zhang; Katsushi Kumata; Tomoteru Yamasaki; Ran Cheng; Akiko Hatori; Longle Ma; Yiding Zhang; Lin Xie; Lu Wang; Hye Jin Kang; Douglas J Sheffler; Nicholas D P Cosford; Ming-Rong Zhang; Steven H Liang
Journal:  ACS Chem Neurosci       Date:  2017-06-13       Impact factor: 4.418

Review 9.  Recent advances in the medicinal chemistry of group II and group III mGlu receptors.

Authors:  Chaobin Jin; Shutao Ma
Journal:  Medchemcomm       Date:  2017-01-13       Impact factor: 3.597

Review 10.  Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.

Authors:  Shalini Dogra; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2021-06-25       Impact factor: 5.273

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.